Press Release
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
05/19/2022
Press Release
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
05/16/2022
Press Release
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
05/12/2022
Full-Year 2021 Earnings Call Transcript
Full-Year 2021 Earnings Call Recording
2021 Audited Annual Consolidated Financial Statements
Q3 2021 Earnings Call Recording
Q2 2021 Management's Discussion and Analysis
Q2 2021 Consolidated Financial Statements
Q1 2021 Management's Discussion and Analysis
Q1 2021 Consolidated Financial Statements
2020 Audited Annual Consolidated Financial Statements
Year-end 2020 Management's Discussion and Analysis
Q3 2020 Management's Discussion and Analysis
Q3 2020 Consolidated Financial Statements
Q2 2020 Management's Discussion and Analysis
Q2 2020 Consolidated Financial Statements
2019 Audited Annual Consolidated Financial Statements
Year-end 2019 Management's Discussion and Analysis
You are leaving MindMed and will be automatically redirected to ${url} in a moment.
Change your mind?
Return to Mindmed
